Jump to page content

Charité/BIH and the Israel Innovation Authority (IIA) have jointly launched a program to promote innovation. This program enables cooperations between excellent clinicians and scientists of Charité/BIH and Israeli startups with immense innovation potential. The funded projects can include R&D activities, clinical trials in all phases, pilot studies, and validation studies. As part of the first IIA Health Tech Pilot Program, four contracts have already been successfully signed as of October 2021. This program had a pilot character at Charité and will also serve as a blueprint for future collaborations with other countries to bring international innovations to Charité. 

 As a result of the good and successful collaboration in the first call, the funding program (International Health-Tech R&D and Pilot Program) has been reopened in September 2022. Israeli startups had the chance to apply to the IIA for cooperation with one of the participating clinics until November 2022. Out of the 72 applications, 17 are addressed to the Charité. Interested Charité/BIH researchers can now partner with a startup until Feb. 20, 2023, to jointly apply for IIA funding for their projects. The second project phase will end with a "full proposal" (June 2023). The profiles and contact details of the startups will be available here from January on.  

The program is internally coordinated by Dr. Hana Hastor (Clinical Study Center/CSC) and Dr. Verena Benz (Charité BIH Innovation/CBI). Please feel free to contact us!

Dr. Hana Hastor

Medical Advisor

Clinical Study Center (CSC), Clinical Trial Unit (CTU)

Contact information
Phone:+49 30 450 643 687
E-mail:hana.hastor@charite.de